# Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

> **NCT04284514** · PHASE1 · COMPLETED · sponsor: **Aerpio Therapeutics** · enrollment: 91 (actual)

## Conditions studied

- Ocular Hypertension
- Primary Open Angle Glaucoma

## Interventions

- **DRUG:** AKB-9778 Ophthalmic Solution
- **DRUG:** Placebo Ophthalmic Solution

## Key facts

- **NCT ID:** NCT04284514
- **Lead sponsor:** Aerpio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-02
- **Primary completion:** 2019-12-15
- **Final completion:** 2019-12-15
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04284514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04284514, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04284514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*